{"SPADE_UN_12099": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_12099", "Peptide Name": "[Lys]7[Lys]11-VmCT1-NH2 (Derived from VmCT1)", "Source": "synthetic construct", "Family": "Not found", "Gene": "Not found", "Sequence": "FLGALWKVAKKVF", "Sequence Length": 13, "UniProt Entry": "No entry found", "Protein Existence": "Synthetic form", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-", "Antifungal"], "Target Organism": "[Ref.31181304] Gram-positive bacteria:Micrococcus luteus A270 (MIC=0.4 μmol/L), Staphylococcus aureus ATCC 29213 (MIC=0.8 μmol/L), Bacillus megaterium ATCC 10778 (MIC=0.4 μmol/L), Staphylococcus epidermidis ATCC 12228 (MIC=6.3 μmol/L);Gram-negative bacteria:Escherichia coli SBS 363 (MIC=3.1 μmol/L)，Serratia marcescens ATCC 4112 (MIC=0.2 μmol/L), Enterobacter cloacae β-12 (MIC=3.1 μmol/L);Fungi:Candida albicans MDM8 (MIC=1.6 μmol/L), Candida tropicalis IOC 4560 (MIC=0.4μmol/L)", "Hemolytic Activity": "[Ref.31181304] 45% hemolysis at 12.5 μmol/L, 100% hemolysis at 50 μmol/L against human red blood cells", "Cytotoxicity": "[Ref.31181304] ①The cell viability of MCF-7 cells induced by [Lys7][Lys11]-VmCT1-NH2 is 105%, 105%, 95%, 85%, 65%, 45%, 25% and 25% at peptide concentrations of 0.8, 1.6, 3.1, 12.5, 25, 50 and 100 μM. ②The cell viability of MCF-10A cells induced by [Lys7][Lys11]-VmCT1-NH2 is 120%, 120%, 85%, 90%, 120% and 120%at peptide concentrations of 0.8, 1.6, 3.1, 6.3, 12.5 and 25 μM.", "Binding Target": "Not found", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Amidation", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C77H119N17O14", "Mass": 1506.87, "PI": 10.3, "Net Charge": 3, "Hydrophobicity": 0.94, "Half Life": "Mammalian:1.1 hourYeast:3 minE.coli:2 min", "Function": "Antibacterial activity against Gram-positive bacteria and Gram-negative bacteria. Antifungal activity against Candida albicans MDM8 and Candida tropicalis IOC 4560.", "Literature": [{"Title": "The effect of lysine substitutions in the biological activities of the scorpion venom peptide VmCT1", "Pubmed ID": "31181304", "Reference": "Eur J Pharm Sci. 2019 Jun 7;136104952. doi 10.1016/j.ejps.2019.06.006.", "Author": "Pedron CN, de Oliveira CS, da Silva AF, Andrade GP, da Silva Pinhal MA, Cerchiaro G, da Silva Junior PI, da Silva FD, Torres MT, Oliveira VX", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=31181304"}], "Frequent Amino Acids": "KAF", "Absent Amino Acids": "CDEHIMNOPQRSTUY", "Basic Residues": 3, "Acidic Residues": 0, "Hydrophobic Residues": 9, "Polar Residues": 7, "Positive Residues": 3, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_13818", "Similarity": 1.0, "Sequence": "KRVNWRKVGRNTALGASYVLSFLG"}, {"SPADE_ID": "SPADE_N_10098", "Similarity": 1.0, "Sequence": "AKKVFKRLGIGKFLHSAKKF"}, {"SPADE_ID": "SPADE_N_10140", "Similarity": 1.0, "Sequence": "AKKVFKRLPKLFSKIWNWK"}]}}}